Original article
Quinacrine in the Treatment of Cutaneous Lupus Erythematosus: Practical Aspects and a Case Series
Aspectos Prácticos de la Quinacrina Como Tratamiento del Lupus Eritematoso Cutáneo: Serie de Casos
Leído
7454
Vecesse ha leído el artículo
3172
Total PDF
4282
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 13 | 12 | 25 |
| 2025 5 | 104 | 44 | 148 |
| 2025 4 | 125 | 37 | 162 |
| 2025 3 | 86 | 31 | 117 |
| 2025 2 | 92 | 46 | 138 |
| 2025 1 | 83 | 41 | 124 |
| 2024 12 | 75 | 42 | 117 |
| 2024 11 | 66 | 55 | 121 |
| 2024 10 | 73 | 61 | 134 |
| 2024 9 | 48 | 46 | 94 |
| 2024 8 | 90 | 63 | 153 |
| 2024 7 | 55 | 49 | 104 |
| 2024 6 | 71 | 39 | 110 |
| 2024 5 | 54 | 39 | 93 |
| 2024 4 | 55 | 34 | 89 |
| 2024 3 | 51 | 42 | 93 |
| 2024 2 | 47 | 45 | 92 |
| 2024 1 | 48 | 60 | 108 |
| 2023 12 | 68 | 39 | 107 |
| 2023 11 | 49 | 24 | 73 |
| 2023 10 | 69 | 36 | 105 |
| 2023 9 | 46 | 30 | 76 |
| 2023 8 | 37 | 16 | 53 |
| 2023 7 | 55 | 50 | 105 |
| 2023 6 | 43 | 23 | 66 |
| 2023 5 | 51 | 41 | 92 |
| 2023 4 | 40 | 12 | 52 |
| 2023 3 | 34 | 22 | 56 |
| 2023 2 | 45 | 22 | 67 |
| 2022 1 | 41 | 33 | 74 |
| 2022 12 | 25 | 39 | 64 |
| 2022 11 | 23 | 44 | 67 |
| 2022 10 | 26 | 17 | 43 |
| 2022 9 | 18 | 47 | 65 |
| 2022 8 | 16 | 55 | 71 |
| 2022 7 | 18 | 25 | 43 |
| 2022 6 | 22 | 38 | 60 |
| 2022 5 | 22 | 31 | 53 |
| 2022 4 | 21 | 32 | 53 |
| 2022 3 | 23 | 48 | 71 |
| 2022 2 | 21 | 19 | 40 |
| 2021 1 | 16 | 39 | 55 |
| 2021 12 | 19 | 38 | 57 |
| 2021 11 | 28 | 46 | 74 |
| 2021 10 | 17 | 47 | 64 |
| 2021 9 | 28 | 44 | 72 |
| 2021 8 | 24 | 23 | 47 |
| 2021 7 | 27 | 31 | 58 |
| 2021 6 | 29 | 31 | 60 |
| 2021 5 | 21 | 27 | 48 |
| 2021 4 | 52 | 45 | 97 |
| 2021 3 | 53 | 34 | 87 |
| 2021 2 | 78 | 32 | 110 |
| 2020 1 | 40 | 16 | 56 |
| 2020 12 | 31 | 10 | 41 |
| 2020 11 | 32 | 20 | 52 |
| 2020 10 | 44 | 20 | 64 |
| 2020 9 | 27 | 19 | 46 |
| 2020 8 | 17 | 27 | 44 |
| 2020 7 | 29 | 12 | 41 |
| 2020 6 | 25 | 24 | 49 |
| 2020 5 | 42 | 25 | 67 |
| 2020 4 | 26 | 17 | 43 |
| 2020 3 | 13 | 18 | 31 |
| 2020 2 | 4 | 15 | 19 |
| 2020 1 | 0 | 4 | 4 |
| 2019 12 | 0 | 9 | 9 |
| 2019 11 | 0 | 5 | 5 |
| 2019 10 | 0 | 4 | 4 |
| 2019 9 | 0 | 2 | 2 |
| 2019 8 | 0 | 1 | 1 |
| 2019 7 | 0 | 6 | 6 |
| 2019 6 | 0 | 11 | 11 |
| 2019 5 | 1 | 51 | 52 |
| 2019 3 | 0 | 3 | 3 |
| 2019 2 | 0 | 2 | 2 |
| 2018 3 | 0 | 1 | 1 |
| 2018 2 | 13 | 6 | 19 |
| 2018 1 | 20 | 4 | 24 |
| 2017 12 | 20 | 8 | 28 |
| 2017 11 | 18 | 5 | 23 |
| 2017 10 | 14 | 4 | 18 |
| 2017 9 | 38 | 6 | 44 |
| 2017 8 | 52 | 9 | 61 |
| 2017 7 | 30 | 4 | 34 |
| 2017 6 | 26 | 14 | 40 |
| 2017 5 | 13 | 9 | 22 |
| 2017 4 | 16 | 8 | 24 |
| 2017 3 | 16 | 12 | 28 |
| 2017 2 | 13 | 8 | 21 |
| 2016 1 | 14 | 6 | 20 |
| 2016 12 | 23 | 15 | 38 |
| 2016 11 | 26 | 8 | 34 |
| 2016 10 | 27 | 12 | 39 |
| 2016 9 | 29 | 14 | 43 |
| 2016 8 | 35 | 10 | 45 |
| 2016 7 | 38 | 9 | 47 |
| 2016 6 | 6 | 12 | 18 |
| 2016 5 | 9 | 10 | 19 |
| 2016 4 | 4 | 0 | 4 |
| 2016 3 | 2 | 1 | 3 |
| 2016 2 | 9 | 3 | 12 |
| 2015 1 | 12 | 2 | 14 |
| 2015 12 | 10 | 0 | 10 |
| 2015 11 | 12 | 2 | 14 |
| 2015 10 | 8 | 11 | 19 |
| 2015 9 | 2 | 3 | 5 |
| 2015 8 | 9 | 4 | 13 |
| 2015 7 | 29 | 26 | 55 |
| 2015 6 | 37 | 11 | 48 |
| 2015 5 | 71 | 25 | 96 |
| 2015 4 | 42 | 29 | 71 |
| 2015 3 | 31 | 32 | 63 |
| 2015 2 | 41 | 18 | 59 |
| 2015 1 | 35 | 16 | 51 |
| 2014 12 | 27 | 13 | 40 |
| 2014 11 | 27 | 18 | 45 |
| 2014 10 | 33 | 19 | 52 |
| 2014 9 | 28 | 19 | 47 |
| 2014 8 | 28 | 24 | 52 |
| 2014 7 | 39 | 22 | 61 |
| 2014 6 | 26 | 11 | 37 |
| 2014 5 | 41 | 15 | 56 |
| 2014 4 | 31 | 12 | 43 |
| 2014 3 | 47 | 22 | 69 |
| 2014 2 | 28 | 14 | 42 |
| 2014 1 | 33 | 23 | 56 |
| 2013 12 | 31 | 15 | 46 |
| 2013 11 | 26 | 25 | 51 |
| 2013 10 | 23 | 29 | 52 |
| 2013 9 | 31 | 22 | 53 |
| 2013 8 | 19 | 28 | 47 |
| 2013 7 | 39 | 31 | 70 |
| 2013 6 | 23 | 36 | 59 |
| 2013 5 | 18 | 31 | 49 |
| 2013 4 | 25 | 32 | 57 |
| 2013 3 | 26 | 34 | 60 |
| 2013 2 | 11 | 13 | 24 |
Mostrar todo
